Matrix metallopeptidase 16 (MMP16) (MMP16)

Matrix metallopeptidase 16 (MMP16), also known as Membrane-type 3 matrix metalloproteinase (MT3-MMP), is a membrane-anchored enzyme that degrades extracellular matrix (ECM) components like collagen and fibronectin [1][2]. It plays a pivotal role in activating pro-MMP2, a key step in facilitating cell invasion and tissue remodeling [1]. In healthy tissues, MMP16 is involved in processes such as angiogenesis and wound healing [2]. However, its overexpression is strongly linked to the progression of various cancers, including melanoma and glioma, where it drives metastasis [3]. Beyond oncology, MMP16 has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD) and cardiovascular conditions [2]. Historically, small molecule inhibitors like marimastat targeted the protein's catalytic site but faced challenges due to poor selectivity and musculoskeletal side effects [4]. Current research focuses on targeting MMP16 mRNA using RNA interference or antisense technologies to specifically silence its expression [3]. These RNA-based approaches aim to overcome the toxicity associated with broad-spectrum protease inhibition. Monitoring MMP16 mRNA levels serves as a potential biomarker for assessing tumor aggressiveness and therapeutic response [3].

Other names

MT3-MMPMembrane-type 3 matrix metalloproteinaseMMP-X2MT-MMP 3Matrix metalloproteinase-16MMP16 mRNA

Inhibition of the catalytic activity of the MMP16 protein or degradation of MMP16 mRNA to prevent protein translation [3][4].